# Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

> **NCT00820222** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 540 (actual)

## Conditions studied

- Metastases, Brain

## Interventions

- **DRUG:** capecitabine
- **DRUG:** lapatinib
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00820222
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-14
- **Primary completion:** 2012-06-11
- **Final completion:** 2018-03-22
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820222, "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00820222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*